Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026

Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026

Same author

Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.

Blood advances·2026

Same author

Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.

The Journal of clinical endocrinology and metabolism·2026

Same author

Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Statistical analysis of disease onset during lifespan with left truncation.

Biometrics·2026

Same journal

Interim analysis in sequential multiple assignment randomized trials for survival outcomes.

Biometrics·2026

Same journal

Acknowledgment of Referees 2025.

Biometrics·2026

Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026

Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026

Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 27, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data.

Irina Ostrovnaya¹, Audrey Mauguen¹, Venkatraman E Seshan¹

¹Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

|March 6, 2020

Summary

This summary is machine-generated.

Comparing tumor mutational profiles helps pathologists determine if a new tumor is a metastasis or a new cancer. A new likelihood ratio test assesses clonal relatedness, even without exact matches.

Keywords:

clonality diagnostic test double primary genomic profiling metastasis

More Related Videos

Characterizing Mutational Load and Clonal Composition of Human Blood

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Dec 27, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Characterizing Mutational Load and Clonal Composition of Human Blood

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Pathology
Genomics

Background:

Distinguishing metastases from independent primary tumors is crucial in cancer care.
Tumor mutational profiling is increasingly used in clinical practice for cancer diagnosis.

Purpose of the Study:

To develop and validate a likelihood ratio test for assessing clonal relatedness between tumors.
To enhance the diagnostic accuracy of differentiating metastases from new primary cancers.

Main Methods:

A novel likelihood ratio test was developed to compare tumor mutational profiles.
The test considers two alternative hypotheses for the origin of clonal cells.
Statistical significance was evaluated even in the absence of exact mutational matches.

Main Results:

The likelihood ratio test provides evidence for clonal relatedness between tumors.
The test can identify metastases even when no direct mutational matches are observed.
Tumor profiles aligning with specific anatomic sites can indirectly indicate metastatic origin.

Conclusions:

The developed likelihood ratio test is a valid tool for assessing tumor clonal relatedness.
This method aids pathologists in distinguishing metastases from independent primary tumors.
Interpreting test results, including indirect evidence, is recommended for clinical application.